Imaging as a surveillance tool in rectal cancer

Expert Review of Medical Devices

Volumn 7, Issue 1, 2010, Pages 99-112

  Bellomi, Massimo ^a   Travaini, Laura Lavinia ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Computed tomography; Diagnostic imaging; Fluorodeoxyglucose; Follow up; Metastases; MRI; PET; PET CT; Rectal cancer

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 DEOXY 3 FLUOROTHYMIDINE F 18; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; OXYGEN 15; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CANCER SCREENING; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; HEALTH CARE AVAILABILITY; HEPATOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; LIVER METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS RADIOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RECTUM CANCER; RECTUM SURGERY; RECURRENT CANCER; REVIEW; SECOND LOOK SURGERY; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING; ANIMAL; ECONOMICS; INSTRUMENTATION; METHODOLOGY; RADIOGRAPHY; RECTUM TUMOR;

ANIMALS; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RECTAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77449134438     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.63     Document Type: Review

References (123)

1. Desch CE, Benson AB 3rd, Somerfeld MR et al. Colorectal cancer surveillance: 2005 update of an American society of clinical oncology practice guideline. J. Clin. Oncol. 23, 8512-8519 (2005). (Pubitemid 46260248)
2. World Cancer Report 2008. Boyle P, Levin B (Eds). World Health Organization, Geneva, Switzerland, 374-378 (2008).
3. Arriola E, Navarro M, Pares D et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. Dis. Colon Rectum 49, 478-484 (2006).
4. Abir F, Alva S, Longo WE et al. The postoperative surveillance of patients with colon cancer and rectal cancer. Am. J. Surg. 192, 100-108 (2006). (Pubitemid 43849615)
5. Pommier R, Woltering EA. Follow-up of patients after primary colorectal cancer resection. Semin. Surg. Oncol. 7, 129-132 (1991).
6. Jessup JM, Menk HR, Fremgen A et al. Diagnosing colorectal carcinoma: clinical and molecular approaches. CA Cancer J. Clin. 47, 70-92 (1997). (Pubitemid 27149866)
7. Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur. J. Cancer 38, 986-999 (2002). (Pubitemid 34442327)
8. Köckerling F, Reymond MA, Altendorf-Hofmann A, Dworak O, Hohenberger W. Infuence of surgery on metachronous distant metastases and survival in rectal cancer. J. Clin. Oncol. 16, 324-329 (1998). (Pubitemid 28041616)
9. Sauer R, Becker H, Hohenberger W et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351(17), 1731-1740 (2004). (Pubitemid 39383208)
10. Abulaf AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br. J. Surg. 81, 7-19 (1994). (Pubitemid 24048923)
11. Titu LV, Nicholson AA, Hartley JE et al. Routine follow-up by magnetic resonance imaging does not improve detection of resectable local recurrences from colorectal cancer. Ann. Surg. 243, 348-352 (2006).
12. Miller AR. Multidisciplinary management of recurrent colorectal cancer. Surg. Oncol. 7, 209-221 (1998).
13. Camilleri-Brennan J, Steele RJ. The impact of recurrent rectal cancer on the quality of life. Eur. J. Surg. Oncol. 27, 349-353 (2001). (Pubitemid 32624535)
14. Goldberg RM, Fleming TR, Tangen CM et al.; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwest Oncology Group. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann. Intern. Med. 129, 27-35 (1998).
15. Huguier M, Houry S, Barrier A. Local recurrence of cancer of the rectum. Am. J. Surg. 182, 437-439 (2001). (Pubitemid 34062837)
16. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-ana lysis. JAMA 284, 1008-1015 (2000). (Pubitemid 30659131)
17. Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet 355, 395-399 (2000).
18. Figueredo A, Rumble RB, Maroun J et al. Follow-up of patients with curatively resecate colorectal cancer: a practice guidelines. BMC Cancer 6, 3-26 (2003). (Pubitemid 38851323)
19. Secco GB, Fardelli R, Rovida S et al. Is intensive follow-up really able to improve prognosis of patients with local recurrence after curative surgery for rectal cancer? Ann. Surg. Oncol. 7, 32-37 (2000). (Pubitemid 30078491)
20. Guillem JG, Chessin DB, Cohen AM et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann. Surg. 241, 829-838 (2005).
21. Longo WE, Johnson FE. The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer. Surg. Clin. North Am. 82, 1091-1108 (2002). (Pubitemid 35463086)
22. Giordano P, Efron J, Vernava AM et al. Strategies of follow-up for colorectal cancer: a survey of the American Society of Colon and Rectal Surgeons. Tech. Coloproctol. 10, 199-207 (2006). (Pubitemid 44546801)
23. Turk PS, Wanebo HJ. Resection of pelvic recurrences. In: Colorectal Cancer. Wanebo HJ (Ed.). CV Mosby, MO, USA, 443-463 (1993).
24. August DA, Ottow RT, Sugenberker PH. Clinical perspectives on human colorectal cancer metastases. Cancer Metastasis Rev. 3, 303-324 (1984).
25. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J. Clin. Oncol. 9(7), 1105-1112 (1991).
26. Saenz NC, Cady B, McDermott WVJ. Experience with colorectal carcinoma metastatic to the liver. Surg. Clin. North Am. 69, 359-368 (1989). (Pubitemid 19092641)
27. Hughes KS, Simon R, Songhorabody S. Resection of the liver for colorectal carcinoma metastasesto the liver: a multi-institutional study of indications for resection. Surgery 103, 278-288 (1988). (Pubitemid 18090426)
28. Gutman F, Alberini J, Wartski M et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am. J. Roentgenol. 185, 495-500 (2005).
29. Antoch G, Saoudi N, Kuehl H et al. Accuracy of whole-body dual-modality fuorine-18-12-fuoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J. Clin. Oncol. 22, 4357-4368 (2004). (Pubitemid 41185156)
30. Bar-Shalom R, Yefremov N, Guralnik L et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J. Nucl. Med. 44, 1200-1209 (2003). (Pubitemid 39655178)
31. Hany TF, Steinert HC, Goerres GW et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225, 575-581 (2002).
32. Park IJ, Kim HC, Yu CS et al. Effcacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur. J. Surg. Oncol. 32, 941-947 (2006).
33. 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J. Nucl. Med. 44, 1797-1803 (2003). (Pubitemid 39663312)
34. Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin. Nucl. Med. 36, 169-181 (2006). (Pubitemid 43320452)
35. Whiteford MH, Whiteford HM, Yee LF et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis. Colon Rectum 43, 759-767 (2000).
36. 18F]FDG PET in clinical oncology. Lancet Oncol. 8, 822-830 (2007). (Pubitemid 47308671)
37. Buck AK, Hetzel M, Schirrmeister H et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur. J. Nucl. Med. Mol. Imaging 32, 525-533 (2005). (Pubitemid 41214194)
38. Francis DL, Freeman A, Visvikis D et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52, 1602-1606 (2003). (Pubitemid 37363445)
39. 18F]3́-fuorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur. J. Nucl. Med. Mol. Imaging 34, 878-883 (2007). (Pubitemid 46798949)
40. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature 359, 843-845 (1992).
41. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J. Nucl. Med. 46, 253-260 (2005). (Pubitemid 43073432)
42. Hicks RJ, Rischkin D, Fisher R et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating an hypoxia-targeting chemotherapy agent. Eur. J. Nucl. Med. Mol. Imaging 32, 1384-1391 (2005). (Pubitemid 41746841)
43. Loi S, Ngan SY, Hicks RJ et al. Oxaliplatin combined with infusional 5-FU and concomitant radiotherapy in inoperable and metastatic rectal cancer: a Phase I trial. Br. J. Cancer 92, 655-661 (2005). (Pubitemid 40460600)
44. Laking GR, West C, Buckley DL et al. Imaging vascular physiology to monitor cancer treatment. Crit. Rev. Oncol. Hematol. 58, 95-113 (2006).
45. Stueckle CA, Haegele KF, Jendreck M et al. Improvements in detection of rectal cancer recurrence by multiplanar reconstruction. Radiologe 45, 930-935 (2005). (Pubitemid 41561594)
46. Stueckle CA, Adams S, Stueckle KF et al. Multi-detector CT in the evaluation of patients with recurrence of rectal cancer. Technol. Cancer Res. Treat. 5, 285-289 (2006). (Pubitemid 43946262)
47. Miles KA, Leggett DA, Kelley BB et al. In vivo assessment of neovascularisation of liver metastases using perfusion CT. Br. J. Radiol. 71, 276-281 (1998). (Pubitemid 128723127)
48. Leggett DA, Kelley BB, Bunce IH et al. Colorectal cancer: diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols. Radiology 205, 716-720 (1997).
49. Lim R P, Lee VS, Bennett GL et al. Imaging the female pelvis at 3.0 T. Top. Magn. Reson. Imaging. 17, 427-443 (2006).
50. Muller-Schimpfe M, Brix G, Layer G et al. Recurrent rectal cancer: diagnosis with dynamic MR imaging. Radiology 189, 881-889 (1993). (Pubitemid 23354512)
51. Dicle O, Obuz F, Cakmakci H. Differentiation of recurrent rectal cancer and scarring with dynamic MR imaging. Br. J. Radiol. 72, 1155-1159 (1999). (Pubitemid 30028927)
52. Torricelli P, Pecchi A, Luppi G et al. Gadolinium-enhanced MRI with dynamic evaluation in diagnosing the local recurrence of rectal cancer. Abdom. Imaging 28, 19-27 (2003). (Pubitemid 36460656)
53. Rudisch A, Kremser C, Judmaier W et al. Dynamic contrast enhanced magnetic resonance imaging: a non-invasive method to evaluate signifcant differences between malignant and normal tissue. Eur. J. Radiol. 53, 514-519 (2005). (Pubitemid 40312144)
54. Tytherleigh MG, Warren BF, Mortensen NJ. Management of early rectal cancer. Br. J. Surg. 95(4), 409-423 (2008).
55. Muthusamy VR, Chang KJ. Optimal methods for staging rectal cancer. Clin. Cancer Res. 13, S6877-S6884 (2007).
56. Ahuja AT, Ying M, Ho SY et al. Ultrasound of malignant cervical lymph nodes. Cancer Imaging 8, 48-56 (2008). (Pubitemid 351517293)
57. Blomqvist L, Holm T, Goranson H et al. MR imaging, CT and CEA scintigraphy in diagnosis of local recurrence of rectal cancer. Acta Radiol. 37, 779-784 (1996). (Pubitemid 126710175)
58. Schaefer M. Langer detection of recurrent rectal cancer with CT, MRI and PET/CT Eur. Radiol. 17, 2044-2054 (2007). (Pubitemid 47097462)
59. 18F-fuorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98, 2930-2934 (2001).
60. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner U, Siegel BA. Utility of FOG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann. Surg. 227, 319-323 (1998). (Pubitemid 28131010)
61. Valk PE, Abella-Columna E, Hasemann MK et al. Whole body PET imaging with F-18 fuorodeoxyglucose in management of recurrent colorectal cancer. Arch. Surg. 134, 503-511 (1999). (Pubitemid 29218121)
62. Delbeke D, Vitola JV, Sandler MP et al. Staging recurrent metastatic colorectal carcinoma with PET. J. Nuc. Med. 38, 1196-1201 (1997). (Pubitemid 27332611)
63. Vitola J V, Delbeke D, Sandier MP et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am. J. Surg. 171, 21-26 (1996). (Pubitemid 26028187)
64. Ruhlmann J, Schomburg A, Bender H et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis. Colon Rectum 40, 1195-1204 (1997). (Pubitemid 27433309)
65. 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J. Nucl. Med. 46, 587-595 (2005).
66. Even-Sapir E, Parag Y, Lerman H et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232, 815-822 (2004). (Pubitemid 39100268)
67. Huebner RH, Park KC, Shepherd JE et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. Nuc. Med. 41, 1177-1189 (2000).
68. Selzner M, Hany T, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann. Surg. 240, 135-139 (2004). (Pubitemid 39602130)
69. Kosharuya M, Jagad RB, Kawamoto J et al. An update and our experience with metastatic liver disease. Hepatogastroenterology 54, 2232-2239 (2007).
70. Huguet El, Old S, Praseedom RK, Balan KK, Gibbs P, Jamieson NV. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Hepatogastroenterology 54, 1667-1671 (2007). (Pubitemid 350068450)
71. Bipat S, Leewen MS, Comans EFI et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-ana lysis. Radiology 237, 123-131 (2005).
72. 18F-FDG: role of primary tumor variables. J. Am. Coll. Surg. 20, 857-868 (2008).
73. Kinkel K, Lu Y, Both M et al. Detection of hepatic metastases from cancer of the gastrointestinal tract by using non invasive imaging methods (US, CT, MR Imaging, PET): a meta-ana lysis. Radiology 224, 748-756 (2002). (Pubitemid 34919808)
74. Glover C, Douse P, Kane P et al. Accuracy of investigations for asymptomatic colorectal liver metastases. Dis. Colon Rectum 45, 476-484 (2002). (Pubitemid 34407725)
75. Quaia E, Di'Onofrio M, Palumbo A et al. Comparison of contrast-enhanced ultrasonography versus aseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confdence. Eur. Radiol. 16, 1599-1609 (2006). (Pubitemid 43871833)
76. Larsen LP, Rosenkilde M, Christensen H et al. The value of contrast enhanced ultrasonography in detection of liver metastases from colorectal cancer: a prospective double-blinded study. Eur. J. Radiol. 62, 302-307 (2007). (Pubitemid 46560336)
77. Haider MA, Amitai MM, Rappaport DC. Multidetector row helical CT in preoperative assessment of small (<1.5 cm) liver metastases: is thinner collimation better? Radiolog y 225; 137-142 (2002).
78. Abdelmoumene A, Chevallier P, Chalaron M et al. Detection of liver metastases under 2 cm: comparison of different acquisition protocols in four row multidetector-CT (MDCT). Eur. Radiol. 15, 1881-1887 (2005). (Pubitemid 41222895)
79. Numminen K, Isoniemi H, Halavaara J et al. Preoperative assessment of focal liver lesions: multidetector computed tomography challenges magnetic resonance imaging. Acta Radiol. 46, 9-15 (2005). (Pubitemid 41673282)
80. Ward J, Robinson PJ, Ashley Guthrie J et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium-and SPIO-enhanced MR imaging. Radiolog y 237, 170-180 (2005). (Pubitemid 41346161)
81. Kim YK, Ko SW, Hwang SB, Kim CS, Yu HC Detection and characterization of liver metastases: 16-slice multidetector computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur. Radiol. 16, 1337-1345 (2006).
82. Ward J, Guthrie JA, Wilson D et al. Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging-comparison of optimized sequences. Radiology 228, 709-718 (2003). (Pubitemid 37025481)
83. Mainenti PP, Mancini M, Mainolf C et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specifc contrast agents. Abdom. Imaging DOI: 10.1007/s00261-009-9555-9562 (2009) (Epub ahead of print).
84. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fuor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 15, 2658-2670 (2005).
85. 18F-FDG PET: a randomized study. J. Nucl. Med. 50, 1036-1041 (2009).
86. Schlemmer HP, Schäfer J, Pfannenberg et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest. Radiol. 40, 64-71 (2005).
87. Schmidt GP, Baur-Melnyk A, Haug A et al. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur. Radiol. 19, 1366-1378 (2009).
88. Zhang C, Chen Y, Xue H et al. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-ana lysis. Int. J. Cancer 124, 167-173 (2009).
89. Beatty JS, Williams HT, Aldridge BA et al. Incidental PET/CT fndings in the cancer patient: how should they be managed? Surgery 146, 274-281 (2009).
90. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J. Nucl. Med. 50, S21-S30 (2009).
91. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J. Nucl. Med. 50, S55-S63 (2009)
92. Vernava AM 3rd, Longo WE, Virgo KS, Coplin MA, Wade TP, Johnson FE. Current follow-up strategies after resection of colon cancer. Results of a survey of the American Society of Colon and Rectal Surgeons. Dis. Colon Rectum 37, 573-583 (1994).
93. Strauss LG, Clorius JH, Schlag P et al. Recurrence of colorectal tumors: PET evaluation. Radiology 170, 329-332 (1989). (Pubitemid 19035648)
94. Slentz K, Senagore A, Hibbert J, Mazier W P, Talbott TM. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am. Surgeon 60, 528-532 (1994). (Pubitemid 24197762)
95. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis. Colon Rectum 37, 272-277 (1994). (Pubitemid 24093768)
96. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270, 943-947 (1993). (Pubitemid 23244732)
97. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg K-G. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis. Colon Rectum 38, 619-626 (1995).
98. Hida J, Yasutomi M, Shindoh K et al. Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Dis. Colon Rectum 39, 74-79 (1996). (Pubitemid 26024896)
99. Northover J. The use of prognostic markers in surgery for colorectal cancer. Eur. J. Cancer 31A(7-8), 1207-1209 (1995).
100. Scott AM, Berlangieri SU, Zalcberg J et al. Detection of recurrent colorectal cancer with F-18-FDG positron emission tomography (PET). J. Nucl. Med. 36, 107P (abstract), (1995).
101. Schiepers C, Penninckx F, De Vadder N et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur. J. Surg. Oncol. 21, 517-522 (1995).
102. 18F] fuorodeoxyglucose in recurrent colorectal cancer. Br. J. Surg. 81, 1666-1670 (1994). (Pubitemid 24349952)
103. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur. J. Nucl. Med. 28, 1758-1765 (2001). (Pubitemid 33141239)
104. 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J. Nucl. Med. 46, 2020-2028 (2005). (Pubitemid 46657449)
105. Park KC, Schwimmer J, Shepherd JE et al. Decision ana lysis for the cost-effective management of recurrent colorectal cancer. Ann. Surg. 233, 310-319 (2001). (Pubitemid 32187808)
106. Padhani AR, Liu G, Koh DM et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11, 102-125 (2009).
107. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18-FDG PET in colorectal cancer: a systematic review J. Nucl. Med. 50, S43-S54 (2009).
108. Goh V, Halligan S, Wellsted DM, Bartram CI. Can perfusion CT assessment of primary colorectal adenocarcinoma blood fow at staging predict for subsequent metastatic disease? A pilot study Eur. Radiol. 19, 79-89 (2009).
109. Zhang XM, Yu D, Zhang HL et al. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis. J. Magn. Reson. Imaging 27(6), 1309-1316 (2008). (Pubitemid 351770682)
110. 18F-FDG PET/CT the diagnostic tool of choice? J. Nucl. Med. 49, 354-361 (2008). (Pubitemid 351355199)
111. Kitajiama K, Murakami K, Yamasaki E et al. Performance of integrated FDG PET/contrast enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast enhanced CT and enhanced CT. Eur. J. Nucl. Med. Mol. Imaging 36, 1388-1396 (2009).
112. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur. J. Nucl. Med. Mol. Imaging 36(Suppl. 1), S113-S120 (2009).
113. Moore HG, Akhurst T, Larson SM, Minsky BD, Mazumdar M, Guillem JG. A case-controlled study of 18-fuorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J. Am. Coll. Surg. 197(1), 22-28 (2003). (Pubitemid 36759175)
114. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation with F-18 fuorodeoxyglucose PET imaging. Abdom. Imaging 22(3), 332-337 (1997).
115. Flamen P, Stroobants S, Van Cutsem E et al. Additional value of whole-body positron emission tomography with fuorine-18-12-fuoro-2-deoxy-D- glucose in recurrent colorectal cancer. J. Clin. Oncol. 17(3), 894-901 (1999). (Pubitemid 29109320)
116. Ogunbiyi OA, Flanagan FL, Dehdashti F et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann. Surg. Oncol. 4(8), 613-620 (1997). (Pubitemid 127725488)
117. Pema PJ, Bennett WF, Bova JG, Warman P. CT vs MRI in diagnosis of recurrent rectosigmoid carcinoma. J. Comput. Assist. Tomogr. 18(2), 256-261 (1994). (Pubitemid 24100013)
118. Stückle CA. [Recurrent rectal cancer: diagnosis by contrast enhancement in MD-CT]. Radiologe 45(11), 1031-1037 (2005).
119. Lai DT, Fulham M, Stephen MS et al. The role of whole-body positron emission tomography with [18F]fuorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch. Surg. 131(7), 703-707 (1996). (Pubitemid 26243630)
120. Fong Y, Saldinger PF, Akhurst T et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am. J. Surg. 178(4), 282-287 (1999).
121. Imdahl A, Reinhardt MJ, Nitzsche EU et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch. Surg. 385(2), 129-134 (2000). (Pubitemid 30202938)
122. Ruers TJ, Langenhoff BS, Neeleman N et al. Value of positron emission tomography with [F-18]fuorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J. Clin. Oncol. 20(2), 388-395 (2002). (Pubitemid 34072520)
123. Ruers T, Bleichrodt R P. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 38(7), 1023-1033 (2002). (Pubitemid 34442330)